Replimune

$34.63
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.12 (-0.35%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Replimune and other stocks, options, and ETFs commission-free!

About REPL

Replimune Group, Inc. Common Stock, also called Replimune, is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA. The listed name for REPL is Replimune Group, Inc. Common Stock.

CEO
Philip Astley-Sparke
Employees
122
Headquarters
Woburn, Massachusetts
Founded
2015
Market Cap
1.67B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
300.50K
High Today
$35.81
Low Today
$33.33
Open Price
$35.34
Volume
288.32K
52 Week High
$54.85
52 Week Low
$8.58

REPL Earnings

-$0.46
-$0.31
-$0.15
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Estimated
— per share
Actual
Expected Jun 3, Pre-Market

You May Also Like

DRH
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure